Mobile

A Phase III, Randomized, Double-Blinded, Multi-Centre Study to Assess the Efficacy of Docetaxel (TAXOTERE™) in Combination with ZD6474 (ZACTIMA™) versus Docetaxel (TAXOTERE™) in combination with Place...

Mise à jour : Il y a 4 ans
Référence : EUCTR2005-004749-32

A Phase III, Randomized, Double-Blinded, Multi-Centre Study to Assess the Efficacy of Docetaxel (TAXOTERE™) in Combination with ZD6474 (ZACTIMA™) versus Docetaxel (TAXOTERE™) in combination with Placebo in Patients With Locally Advanced or Metastatic (Stage IIIb – IV) Non-small Cell Lung Cancer (NSCLC) after Failure of 1st Line Anti-Cancer Therapy

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

The primary objective of this study is to demonstrate an improvement in PFS in the combination of ZACTIMA with docetaxel compared with docetaxel plus placebo in patients with locally advanced or metastatic NSCLC after failure of 1st line anti-cancer therapy

Critère d'inclusion

  • non-small cell lung cancer

Liens